» Articles » PMID: 25126392

Type 2 Diabetes and Cardiovascular Disease: Have All Risk Factors the Same Strength?

Overview
Specialty Endocrinology
Date 2014 Aug 16
PMID 25126392
Citations 319
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease. Most of this excess risk is it associated with an augmented prevalence of well-known risk factors such as hypertension, dyslipidaemia and obesity in these patients. However the improved cardiovascular disease in type 2 diabetes mellitus patients can not be attributed solely to the higher prevalence of traditional risk factors. Therefore other non-traditional risk factors may be important in people with type 2 diabetes mellitus. Cardiovascular disease is increased in type 2 diabetes mellitus subjects due to a complex combination of various traditional and non-traditional risk factors that have an important role to play in the beginning and the evolution of atherosclerosis over its long natural history from endothelial function to clinical events. Many of these risk factors could be common history for both diabetes mellitus and cardiovascular disease, reinforcing the postulate that both disorders come independently from "common soil". The objective of this review is to highlight the weight of traditional and non-traditional risk factors for cardiovascular disease in the setting of type 2 diabetes mellitus and discuss their position in the pathogenesis of the excess cardiovascular disease mortality and morbidity in these patients.

Citing Articles

Identifying and ranking non-traditional risk factors for cardiovascular disease prediction in people with type 2 diabetes.

Dziopa K, Chaturvedi N, Asselbergs F, Schmidt A Commun Med (Lond). 2025; 5(1):77.

PMID: 40082712 PMC: 11906859. DOI: 10.1038/s43856-025-00785-y.


Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies.

Bayanati M, Ismail Mahboubi Rabbani M, Sirous Kabiri S, Mir B, Rezaee E, Tabatabai S Iran J Pharm Res. 2025; 23(1):e151581.

PMID: 40066124 PMC: 11892788. DOI: 10.5812/ijpr-151581.


Role of Echocardiography in Detecting Left Ventricular Dysfunction Among Diabetic Patients: A Clinical and Biochemical Perspective.

Siripuram C, Mahendran K, Hegde S, Murali Krishna S, Suresh Suvarna S, Kandimalla R Cureus. 2025; 17(2):e78720.

PMID: 40065867 PMC: 11891462. DOI: 10.7759/cureus.78720.


A Resampling Approach for Causal Inference on Novel Two-Point Time-Series with Application to Identify Risk Factors for Type-2 Diabetes and Cardiovascular Disease.

Dai X, Mouti S, Vale M, Ray S, Bohn J, Goldberg L Stat Biosci. 2025; 17(1):78-131.

PMID: 40061216 PMC: 11889075. DOI: 10.1007/s12561-023-09390-w.


Chronic complications of type 2 diabetes and associated factors: a cross-sectional study at the Moulay Hassan Hospital in Kenitra, Morocco.

El Aameri M, Jaghror I, Meskini N, Benchehida H, Eladha I, Chakit M Pan Afr Med J. 2025; 49:84.

PMID: 40027088 PMC: 11871885. DOI: 10.11604/pamj.2024.49.84.42930.


References
1.
Han T, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S . Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002; 25(11):2016-21. DOI: 10.2337/diacare.25.11.2016. View

2.
Raz I, Wilson P, Strojek K, Kowalska I, Bozikov V, Gitt A . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009; 32(3):381-6. PMC: 2646013. DOI: 10.2337/dc08-1671. View

3.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M . European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted.... Eur Heart J. 2012; 33(13):1635-701. DOI: 10.1093/eurheartj/ehs092. View

4.
Jialal I, Stein D, Balis D, Grundy S, Adams-Huet B, Devaraj S . Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103(15):1933-5. DOI: 10.1161/01.cir.103.15.1933. View

5.
Adetunji O, Adeleye J, Agada N, Salako B . Microalbuminuria and clinical correlates in black African patients with type 2 diabetes. West Afr J Med. 2007; 25(4):279-83. View